High blood pressure, or hypertension, is often experienced among individuals who have been diagnosed with diabetes. A diabetes inhibitor is a way to control the effects of high blood pressure, and thus helps alleviate many of the shared problems between diabetes and high blood pressure. In addition, a diabetes inhibitor will reduce the risk of other conditions associated with the disease, such as diabetic retinopathy and diabetic nephropathy. A person with diabetes who experiences coincidental heart-related problems will often have to deal with longer hospital stays and higher medical costs as a result than a non-diabetic. This being the case, it is important to treat problems like high blood pressure using a diabetes inhibitor along the positive effects gained by using it to combat the disease itself. It is necessary, of course, to regulate the use of diabetes inhibitors because of the risk of lowering the blood pressure to unsafe levels, at which point a patient may suffer from hypotension, as well as other side effects such as cough, headache, tiredness and/or nausea.

Angiotension-converting enzyme (ACE) inhibitors are readily available in the United States, and they include drugs like captopril, enalapril, lisinopril and ramipril. Their primary effect is to increase the capacity of blood veins, resulting in higher output from the heart and ultimately lowering blood pressure. This results in a decrease in chance for heart failure in patients both diabetic and non-diabetic. When specifically used as a diabetes inhibitor, these drugs are helpful in dealing with diabetic conditions such as kidney disease, or nephropathy, and diabetic retinopathy. Diabetes inhibitors do not, however, lower blood sugar directly – the lowering of blood sugar levels can be achieved through other means, such as dietary supplements, insulin injections and even the correct use of proper herbs as well as responsible changes in an individual’s diet and exercise routines. If negative side effects or reactions occur as a result of the use of angiotension-converting enzyme inhibitors, a patient may use the alternative angiotension receptor blockers, or ARBs, which have also proven effective in dealing with the aforementioned problems, both diabetes-related and not.


PKC Inhibitor – Diabetes and Protein Kinase C


In diabetic patients with high blood glucose levels, there is often an accompanying surplus creating of PKC-beta, or Protein Kinase C-beta. Excess levels of this enzyme will cause creation of new blood vessels, which can cause complication in a diabetic patient, so new research and field trials have proven that, in some cases, blocking the creation of PKC-beta can eliminate some of these potential problems, which include the aforementioned diabetic retinopathy and diabetic nephopathy. While research in this particular area is still ongoing, there are strong indications that when reducing the PKC-beta enzyme, the possibility of diabetic retinopathy and nepropathy formation is reduced. As research continues in the fields of a true diabetes inhibitor as well as a PKC inhibitor, the fact remains that the most important thing for a diabetic individual to focus on is control of blood sugar levels, whether through diet, exercise, the right medications, or a combination of all of the above.